Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1220 participants.
Also called NCT06401616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,220 participants
- Sponsor
- Registry
-
NCT06401616
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Recruiting
Technical summary
Registry record NCT06401616. Randomized; single masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2028-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
- Condition
- Atrial Fibrillation
- Condition
- Left Atrial Appendage Absent
- Condition
- Anticoagulant Adverse Reaction
- Intervention (Drug)
- OAC will be discontinued for the duration of the trial
- Lead sponsor
- Odense University Hospital
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
- Collaborator
- Gødstrup Hospital
- Collaborator
- Aarhus University Hospital
- Collaborator
- Aalborg University Hospital
- Collaborator
- Population Health Research Institute
- Collaborator
- Region of Southern Denmark
Record details
- Record id
cardio:ct-nct06401616- Content hash
6c64096e35e1f022d395099ffac081fb599341f17b0060c30e8fa0763c5fd675